Third-line treatment in metastatic renal cell carcinoma and bone metastases

Affiliations

Daniel Y C Heng. Can Urol Assoc J. 2015 Jul-Aug.

. 2015 Jul-Aug;9(7-8):268.

doi: 10.5489/cuaj.3238.

No abstract available

Comment on

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.
Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G. Iacovelli R, et al. Can Urol Assoc J. 2015 Jul-Aug;9(7-8):263-7. doi: 10.5489/cuaj.2377. Can Urol Assoc J. 2015. PMID: 26316911 Free PMC article.

1. Iacovelli R, Santini D, Rizzo M, et al. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Can Urol Assoc J. 2015;9:263–7. doi: 10.5489/cuaj.2377. - DOI - PMC - PubMed
1. Mckay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577–84. doi: 10.1016/j.eururo.2013.08.012. - DOI - PMC - PubMed
1. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US); 2013. Jun, Identifier NCT01865747, A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy. https://clinicaltrials.gov/ct2/show/NCT01865747. Accessed July 31, 2015.
1. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US); 2012. Sep, Identifier NCT01668784, A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy. https://clinicaltrials.gov/ct2/show/NCT01668784. Accessed July 31, 2015.